Aethoxysklerol

Primær information

  • Handelsnavn:
  • Aethoxysklerol 30 mg/ml injektionsvæske, opløsning
  • Dosering:
  • 30 mg/ml
  • Lægemiddelform:
  • injektionsvæske, opløsning
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Allopatiske stof

Dokumenter

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Aethoxysklerol 30 mg/ml injektionsvæske, opløsning
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Lægemiddelstyrelsen - Danish Medicines Agency
  • Autorisation status:
  • Markedsført
  • Autorisationsnummer:
  • 06905
  • Sidste ændring:
  • 02-02-2018

Indlægsseddel

Aethoxysklerol injektionsvæske, opløsning 5 mg/ml, 10 mg/ml, 30 mg/ml

I henhold til §11 i den gældende bekendtgørelse om mærkning m.m. af lægemidler* er

der ikke udarbejdet en indlægsseddel for dette produkt.

MediLink AS, juni 2010

* I §11 i bekendtgørelse nr. 1210 af 7. december 2007 fremgår det, at: ”Indlægssedlen

kan udelades, hvis lægemidlet er beregnet til udelukkende at skulle administreres af

sundhedspersonale eller dyrlæger, og hvis lægemidlet ikke er beregnet til

langtidsvirkende effekt.”

18-4-2018

TruPet LLC Recalls Boost Me Mighty Meaty Beef Topper Meal Enhancer Because of Possible <em>Salmonella</em> Contamination

TruPet LLC Recalls Boost Me Mighty Meaty Beef Topper Meal Enhancer Because of Possible <em>Salmonella</em> Contamination

TruPet, LLC of Milford, OH, is voluntarily recalling a limited amount of Boost Me Mighty Meaty Beef Topper Meal Enhancer because the products have the potential to be contaminated with Salmonella. The recall is limited to 400 cases of the product, as identified below.

FDA - U.S. Food and Drug Administration

13-2-2018

Acyclovir 400mg Tablets by Apace Packaging: Recall - Product Mix-up

Acyclovir 400mg Tablets by Apace Packaging: Recall - Product Mix-up

Missing a dose of Acyclovir Tablets could cause a reactivation of a virus being treated.

FDA - U.S. Food and Drug Administration

13-2-2018

Apace Packaging LLC Issues Voluntary Nationwide Recall of Acyclovir (Lot 19900) Due to Product Mix-up

Apace Packaging LLC Issues Voluntary Nationwide Recall of Acyclovir (Lot 19900) Due to Product Mix-up

Apace Packaging LLC is voluntarily recalling one lot of Acyclovir Tablet, USP, 400mg, 50ct Unit Dose, NDC# 50268-061-15, Lot Number 19900, to the Retail level. These products have been recalled due to a product mix-up. A small number of blister cards containing Acyclovir Tablets, 400mg, UD Blister Cards may potentially also include Torsemide, 20mg, Tablets.

FDA - U.S. Food and Drug Administration

1-2-2018

Scientific guideline:  Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First version, adopted

Scientific guideline: Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First version, adopted

This guidance provides product-specific guidance on the demonstration of the dronedarone.

Europe - EFSA - European Food Safety Authority EFSA Journal

4-8-2017

FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants

FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants

[8-03-2011] The U.S. Food and Drug Administration (FDA) is informing the public that chronic, high doses (400-800 mg/day) of the antifungal drug Diflucan (fluconazole) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.

FDA - U.S. Food and Drug Administration

15-6-2017

Statement from FDA Commissioner Scott Gottlieb, M.D., on the 2016 National Youth Tobacco Survey results

Statement from FDA Commissioner Scott Gottlieb, M.D., on the 2016 National Youth Tobacco Survey results

While the latest numbers from the 2016 National Youth Tobacco Survey are encouraging, it is critical that we work to ensure this downward trend continues over the long term across all tobacco products. Every day in the U.S., more than 2,500 youth under the age of 18 smoke their first cigarette and more than 400 youth become daily cigarette smokers. It is also clear from these most recent numbers that youth are continuing to experiment with, or becoming regular users of, a wide range of other tobacco pro...

FDA - U.S. Food and Drug Administration

19-6-2015

Global operation against illicit medicines completed

Global operation against illicit medicines completed

A global medicine operation results in 156 arrests and shutdown of more than 2,400 websites.

Danish Medicines Agency

31-1-2018

Scientific guideline:  Draft ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, draft: consultation open

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

14-12-2017

ANTI-AGING FOUNDATION SPF 15 SHADE 400 (Octinoxate) Emulsion [La Prairie, Inc.]

ANTI-AGING FOUNDATION SPF 15 SHADE 400 (Octinoxate) Emulsion [La Prairie, Inc.]

Updated Date: Dec 14, 2017 EST

US - DailyMed

12-12-2017

SYSTANE (Polyethylene Glycol 400 And Propylene Glycol) Gel [Alcon Laboratories, Inc.]

SYSTANE (Polyethylene Glycol 400 And Propylene Glycol) Gel [Alcon Laboratories, Inc.]

Updated Date: Dec 12, 2017 EST

US - DailyMed

31-10-2017

MUCUS RELIEF (Guaifenesin 400 Mg) Tablet [Advance Pharmaceutical Inc.]

MUCUS RELIEF (Guaifenesin 400 Mg) Tablet [Advance Pharmaceutical Inc.]

Updated Date: Oct 31, 2017 EST

US - DailyMed

30-10-2017

MUCUS RELIEF (Guaifenesin 400 Mg) Tablet [Richmond Pharmaceuticals, Inc.]

MUCUS RELIEF (Guaifenesin 400 Mg) Tablet [Richmond Pharmaceuticals, Inc.]

Updated Date: Oct 30, 2017 EST

US - DailyMed

28-7-2017

Scientific guideline:  Draft dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First version, draft: consultation open

Scientific guideline: Draft dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First version, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of dronedarone film-coated tablets

Europe - EMA - European Medicines Agency

6-6-2017

MUCUS RELIEF (Guaifenesin 400 Mg) Tablet [HealthLife Of USA LLC]

MUCUS RELIEF (Guaifenesin 400 Mg) Tablet [HealthLife Of USA LLC]

Updated Date: Jun 6, 2017 EST

US - DailyMed